Glycine Transport Inhibitors for the Treatment of Schizophrenia

Kenji Hashimoto*
From the Division of Clinical Neuroscience, Chiba University Center for Forensic, Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan

© Kenji Hashimoto; Licensee Bentham Open

open-access license: This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

* Address correspondence to this author at the From the Division of Clinical Neuroscience, Chiba University Center for Forensic , Mental Health, 1-8-1 Inohana, Chiba 260-8670, Japan; Tel: +81-43-226-2147, Fax: +81-43-226-2150; Email:


Multiple lines of evidence indicate that hypofunction of glutamatergic neurotransmission via N-methyl-D-aspartate (NMDA) receptors might be implicated in the pathophysiology of schizophrenia, suggesting that increasing NMDA receptor function via pharmacological manipulation could provide a new strategy for the management of schizophrenia. Currently, the glycine modulatory sites on NMDA receptors present the most attractive therapeutic targets for the treatment of schizophrenia. One means of enhancing NMDA receptor neurotransmission is to increase the availability of the obligatory co-agonist glycine at modulatory sites on the NMDA receptors through the inhibition of glycine transporter-1 (GlyT-1) on glial cells. Clinical studies have demonstrated that the GlyT-1 inhibitor sarcosine (N-methyl glycine) shows antipsychotic activity in patients with schizophrenia. Accordingly, a number of pharmaceutical companies have developed novel and selective GlyT-1 inhibitors for the treatment of schizophrenia. This paper provides an overview of the various GlyT-1 inhibitors and their therapeutic potential.

Keywords: Schizophrenia, NMDA receptor, Glutamate, Glycine, Transporter, Glia.


A growing body of evidence suggests that the N-methyl-D-aspartate (NMDA) receptors (Fig. 1) play a role in the pathophysiology of schizophrenia [1-12]. Subanesthetic doses of the non-competitive NMDA receptor antagonist phencyclidine (PCP; Fig. 2) have been shown to produce a wide range of transient schizophrenia-like symptoms, including estrangement, loss of body boundaries, formal thought disorder, hallucinations, and psychosis [1,13,14]. In addition, PCP is known to dramatically exacerbate the symptoms of schizophrenia [1,13,14]. In a randomized, double-blind, placebo-controlled study, Krystal and co-workers [15] reported that the non-competitive NMDA receptor antagonist ketamine (Fig. 2) produced positive and negative symptoms in a dose-dependent manner. A high dose of ketamine elicited significant perceptual effects, including altered perceptions of the body, environment, and time. In another double-blind, placebo-controlled study, Malhotra et al. [16] reported that ketamine produced brief psychosis marked by thought disorder and withdrawal-retardation in healthy volunteers. Furthermore, a double-blind, crossover-design study revealed that ketamine alters mood in healthy volunteers [17]. Moreover, in a double-blind, placebo-controlled study, Lahti et al. [18] reported that ketamine induced a brief (less than 30 minutes), dose-related worsening of positive symptoms in schizophrenic patients maintained on haloperidol. In contrast, Zarate et al. [19] demonstrated the robust and rapid (within 2 h) antidepressant effects of a single dose of ketamine (0.5 mg/kg, i.v. infusion for 40 min) in treatment-resistant major depression, suggesting the role of NMDA receptors in the rapid antidepressant activity of ketamine [20-22].

Fig. (1).

The NMDA receptor complex Glutamate and NMDA bind to the agonist site on NMDA receptors. Phencyclidine (PCP), ketamine, and dizocilpine ((+)-MK-801) bind to PCP-receptor in the inside of the NMDA receptors. Glycine and D-serine bind to co-agonist site (glycine modulatory site) on the NMDA receptors.

Fig. (2).

Chemical structures of phencyclidine (PCP), ketamine, and dizocilpine ((+)-MK-801).

In addition to glutamate, the NMDA receptors are modulated by glycine, D-serine, polyamines, and specific divalent cations, including magnesium and zinc [9-12] (Fig. 1). Glycine and D-serine (Fig. 3) act as obligatory co-agonists at the glycine modulatory sites on the NMDA receptors to regulate glutamatergic transmission. Currently, the glycine modulatory sites on the NMDA receptors are the most attractive therapeutic targets for schizophrenia. This review article provides an overview of glycine transporter-1 (GlyT-1) inhibitors as a potential therapeutic approach to the treatment of schizophrenia.

Fig. (3).

Chemical structures of glycine, sarcosine (N-methyl glycine), D-serine, and D-cycloserine


Glycine (Fig. 3) was first proposed to act as a neurotransmitter in the mammalian spinal cord in 1965 [23]. Glycine is now among the well-characterized amino acid neurotransmitters in the mammalian CNS, where it is known to act as an inhibitory transmitter via its interaction with strychnine-sensitive glycine receptors [24-29]. It also plays an important role in excitatory neurotransmission via strychnine-insensitive glycine sites located on the NMDA receptors [26-29].

The plasma levels of total serine (L- and D-serine) and glycine in patients with schizophrenia are higher than those of controls [30], and the levels of serine and glycine in the brains of schizophrenic patients are higher than those of controls [30,31], suggesting a possible abnormality in serine hydroxymethyltransferase, by which glycine is converted to L-serine [10]. Interestingly, it has been reported that serum D-serine levels and the D-serine/total serine ratio in patients with schizophrenia are significantly lower than those of healthy control subjects, supporting the hypothesis of NMDA receptor hypofunction in schizophrenia [8].

Given the NMDA receptor hypofunction hypothesis of schizophrenia, increasing NMDA receptor function by glycine may be a potential strategy for the management of schizophrenia. Recent retrospective analyses have suggested that NMDA receptor agonists are effective at the treatment of persistent negative symptoms and cognitive deficits of schizophrenia, and that the full agonist glycine may be more effective than the partial agonist D-cycloserine (Fig. 3) [32].


In the CNS, synaptic levels of glycine are regulated by specific sodium/chloride-dependent transporters. The effects of glycine in the synapse are terminated by its rapid reuptake into the nerve terminal and adjacent glial cells via high-affinity glycine transporters referred to as GlyT-1 and GlyT-2. GlyT-1 and GlyT-2 possess 12 putative transmembrane spanning domains, and share approximately 50% amino acid sequence identity [26-29,33,34]. GlyT-1 is widely expressed in the CNS, where it is predominantly present on glial cells. It is likely that GlyT-1 is responsible for glycine reuptake in forebrain areas, and in some regions, it may be co-localized with strychnine-insensitive glycine modulatory sites on the NMDA receptors [33-39]. A recent study demonstrated that glycine transport might maintain local synaptic glycine at very low levels, suggesting that GlyT-1 could play a role in regulating glutamatergic neurotransmission via NMDA receptors [40]. In contrast to GlyT-1, GlyT-2 has a predominantly neuronal and more limited distribution, being primarily restricted to the spinal cord, brainstem, and cerebellum [38]. Indeed, GlyT-2 is known to be co-localized with strychnine-sensitive glycine receptors, suggesting that GlyT-2 may be a reliable marker for glycinergic neurons [26-29].

In an attempt to clarify the in vivo functional roles of glycine transporters in the CNS, knockout mice deficient in the GlyT-1 gene have been generated [41,42]. Newborn mice deficient in the GlyT-1 gene are anatomically normal, but show severe motor and respiratory deficits and die during the first postnatal day [41]. Glycine or the GlyT-1 inhibitor sarcosine (N-methyl glycine; Fig. 3) were found to suppress respiratory activity in slices from wild-type mice. During early postnatal life, GlyT-1 is essential for regulating glycine levels at inhibitory glycine receptors, and GlyT-1 deletion generates symptoms found in human glycine encephalopathy [41]. Furthermore, heterozygous knockout mice (reduced expression of GlyT-1) show enhanced hippocampal NMDA receptor function and memory retention, and are protected against disruptions of sensory gating induced by amphetamine, which suggests that GlyT-1 inhibitors might bring about both cognitive enhancement and antipsychotic effects [42]. Mice heterozygous for the GlyT-1 gene show faster decay kinetics, reduced ifenprodil sensitivity, and increased zinc-induced antagonism in NMDA receptor currents [42]. These findings highlight the importance of GlyT-1 in the regulation of glutamatergic neurotransmission. Taken together, the data suggest that increasing synaptic levels of glycine by inhibition of its uptake will lead to enhanced NMDA receptor activation, in turn suggesting a potential role for GlyT-1 inhibitors as a novel treatment for schizophrenia [43-55].


Glycine is an endogenous compound that is actively metabolized and sequestered in the brain. Glycine is extensively metabolized in the liver, and only poorly crosses the blood-brain barrier. Therefore, a large amount of glycine is needed for the treatment of schizophrenia [32]. Thus, the ability of glycine levels to modulate NMDA receptor-mediated neurotransmission suggests that the pharmacological manipulation of synaptic glycine might be effective in the treatment of conditions involving NMDA receptor hypofunction [1,43-55].

The NMDA receptor antagonist PCP (Fig. 2) has been widely used in studies of animal models of schizophrenia [9-11,56,57]. We previously reported that repeated administration of PCP (10 mg/kg/day for 10 days) caused long-term cognitive deficits in mice (more than 6 weeks after the final administration of PCP), and that PCP-induced cognitive deficits could be improved by subsequent subchronic (2 weeks) administration of clozapine, but not haloperidol [58]. Therefore, the reversal of PCP-induced cognitive deficits may be a potential animal model of atypical antipsychotic activity, i.e., this model may be beneficial in terms of ameliorating the cognitive deficits in people with schizophrenia [59-67]. Using this model, we reported that treatment with the selective GlyT-1 inhibitor, (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (NFPS, ALX 5407; Fig. 4) [68-71], attenuated PCP-induced cognitive deficits in mice [64]. We also found that repeated administration of PCP caused increased levels of GlyT-1 protein in the mouse hippocampus, and that extracellular glycine levels in the hippocampus of PCP-treated mice were lower than those of control mice [64]. Furthermore, NFPS inhibited PCP-induced hyperactivity in mice, and NFPS reversed PCP-induced changes in electroencephalogram (EEG) power spectra in conscious rats [71]. It has been reported that NFPS induced a pattern of c-Fos immunoreactivity comparable with the atypical antipsychotic drug clozapine, and that NFPS enhanced prepulse inhibition (PPI) of the acoustic startle response in DBA/2J mice, a strain with low basal levels of PPI [72]. Moreover, to the same degree as by clozapine or D-serine, NFPS was able to reverse persistent latent inhibition (LI) [72] and cognitive deficits [73] induced by the NMDA receptor antagonist dizocilpine ((+)-MK-801; Fig. 2). Manahan-Vaughan et al. [74] reported that NFPS could rescue hippocampal long-term potentiation and learning deficits in freely behaving rats after systemic administration of dizocilpine. All these findings suggest that GlyT-1 inhibitors could potentially serve as therapeutic drugs to treat the cognitive deficits associated with schizophrenia.

Fig. (4).

Chemical structure of (R)-(N-[3-(4'-fluorophenyl)-3-(4'- phenylphenoxy)propyl])sarcosine (NFPS, ALX 5407).

Researchers at Sanofi-Synthelabo Recherche reported the detailed neuropharmacological profile of SSR 504734 (Fig. 5) as part of a biochemical approach to developing a selective and reversible GlyT-1 inhibitor [75]. SSR 504734, a selective and reversible inhibitor of GlyT-1, blocked the ex vivo uptake of glycine in a rapid, reversible, and long-term manner. In animal models of schizophrenia, this compound normalized spontaneous PPI deficits in DBA/2 mice, and reversed both amphetamine-induced locomotor hyperactivity as well as selective attention deficits in adult rats treated neonatally with PCP. These findings suggest that SSR 504734 is a potent and selective GlyT-1 inhibitor that exhibits ameliorative effects in animal models of schizophrenia; this compound may therefore be efficacious not only in treating positive, but also negative symptoms (i.e., cognitive deficits) of schizophrenia [75]. Moreover, it has been reported that SSR 504734 (10 mg/kg) enhanced the facilitatory influence of glutamatergic afferents on dopamine neurotransmission in the nucleus accumbens, and this synergistic effect was found to be dependent on glutamatergic tone [76]. Furthermore, SSR 504734 is reported to be effective in the PCP-induced functional activation in the cortico-limbo-thalamic circuits [77] and working memory deficits [78]. Moreover, SSR 504734 attenuated PCP-induced hyperlocomotion in mice, but potentiated the motor stimulant and motor depressant effects of amphetamine and apomorphine, respectively [79].

Fig. (5).

Chemical structure of SSR 504734

Recently, researchers at the Sanofi-Synthelabo Recherche Institute reported the detailed neuropharmacological profile of SSR 103800, a novel selective and reversible GlyT-1 inhibitor. They demonstrated that SSR 103800 elevates central glycine levels in the prefrontal cortex, and it exhibits potential therapeutic activity in animal models considered representative of the positive, cognitive, and depressive symptoms observed in patients with schizophrenia [80]. SSR 103800 (1 and 3 mg/kg) and SSR 504734 (1 and 10 mg/kg) potentiated latent inhibition (LI) under conditions where LI was not present in non-treated controls and SSR 103800 (1 mg/kg) reversed amphetamine-induced disrupted LI while not affecting LI on its own. Additionally, SSR 103800 (1 and 3 mg/kg) and SSR 504734 (3 and 10 mg/kg) reversed abnormally persistent LI induced by dizocilpine. In the neurodevelopmental model, SSR 504734 (3 and 10 mg/kg) reverted the LI back to control (normal) levels [78]. These preclinical data from acute and neurodevelopmental models suggest that GlyT-1 inhibitors could exhibit activity in the positive, negative, and cognitive symptom domains of schizophrenia.

Researchers at Merck Research Laboratories reported the pharmacological profile of a class of novel GlyT-1 inhibitors related to 4,4-disubstituted piperidines, including 2-methoxy-N-{1-[4-phenyl-1-(propylsulfonyl)piperidin-4-yl]-methyl}benzamide (compound 1: Fig. 6) and 2-amino-6-chloro-N-{(1S)-1-[4-phenyl-1-(propylsulfonyl)-piperidin-4-yl]ethyl}benzamide (compound 2: Fig. 6) [81,82]. A rapid and sustained increase in the extracellular levels of glycine in the prefrontal cortex of freely moving rats was observed at all three experimental doses (1, 3, 10 mg/kg, s.c.) of this compound. Furthermore, this compound was found to significantly enhance PPI at three different doses (3, 30, 100 mg/kg, s.c.) in DBA/2J mice. Brain levels of this compound ranged from 400 nM to 2300 nM during the time course of the PPI experiments. By selectively increasing extracellular glycine levels in the prefrontal cortex via the inhibition of GlyT-1, this compound significantly enhanced performance in a behavioral animal model of sensorimotor gating [81].

Fig. (6).

Chemical structure of compound 1 (2-methoxy-N-{[4-phenyl-1-(propylthio)piperidin-4-yl]methyl}benzamide) and compound 2 (2- amino-6-chloro-N-{(1S)-1-[4-phenyl-1-(propylthio)piperidin-4-yl]ethyl}benzamide).

Researchers at F. Hoffmann-La Roche, Ltd. reported a novel series of N-(2-aryl-cyclohexyl) substituted spiropiperidines (compound 3-7: Fig. 7) as highly selective GlyT-1 inhibitors [83-87]. Furthermore, a potent and selective GlyT-1 inhibitor 4-(4-{[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]carbonyl}piperazin-1-yl)-3-fluorobenzonitrile (compound 8: EC50 = 16 nM for GlyT-1)(Fig. 8) increased extracellular glycine levels in the mouse striatum after oral administration [88].

Fig. (7).

Chemical structures of compound 3, (1-phenyl-8-[(1S,2S)-2-phenylcyclohexyl]-1,3,8-triazaspiro[4.5]decan-4-one), compound 4, (8- [(1S,2R)-2-hydroxy-2-phenylcyclohexyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one), compound 5, ((4R)-4-phenyl-8-[(1S,2S)-2- phenylcyclohexyl]-2,8-diazaspiro[4.5]decan-1-one), compound 6, ((4R)-8-[(1S,2R)-2-hydroxy-2-phenylcyclohexyl]-4-phenyl-2,8- diazaspiro[4.5]decan-1-one), and compound 7, (4-(4-fluorophenyl)-8-[1-(4-fluorophenyl)cyclohexyl]-2,8-diazaspiro[4.5]decan-1-one).

Fig. (8).

Chemical structure of compound 8, 4-(4-{[2- (cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]carbonyl}piperazin- 1-yl)-3-fluorobenzonitrile.

Researchers at H. Lundbeck A/S developed the compound (R)-4-[5-chloro-2-(4-methoxy-phenylsulfanyl)-phenyl]-2-methyl-piperazin-1-yl-acetic acid (compound 9: IC50 = 150 nM) (Fig. 9), which was shown to elevate extracellular glycine levels in the rat ventral hippocampus, as measured by in vivo microdialysis at doses of 1.2-4.6 mg/kg (s.c.) [89]. Furthermore, the same group reported the new compound (S)-1-{2-[3-(3-fluoro-phenylsulfanyl)biphenyl-4-yloxy]ethyl}pyrrolidine-2-carboxylic acid (compound 10: IC50 = 59 nM) [90] (Fig. 9). In vitro and in vivo assessments revealed that the CNS utility of this class of compounds might be diminished due to active efflux transporter activity [90].

Fig. (9).

Chemical structure of compound 9, (R)-4-[5-chloro-2-(4- methoxy-phenylsulfanyl)-phenyl]-2-methyl-piperazin-1-yl-acetic acid and compound 10, (S)-1-{2-[3-(3-fluoro-phenylsulfanyl) biphenyl-4-yloxy]ethyl}pyrrolidine-2-carboxylic acid.

ORG 25935 (cis-N-methyl-N-(6-methoxy-1-phenyl-1,2,3,4-tetrahydronaphthalen-2- ylmethyl)amino-methylcarboxylic acid hydrochloride)( Fig. 10) is a GlyT-1 inhibitor that easily crosses the blood-brain barrier. ORG 25935 (6 mg/kg, i.p.) was shown to increase striatal extracellular glycine levels by ~50-80% for ~2.5 hours [91]. Molander et al. [92] reported that ORG 25935 decreased ethanol intake and ethanol preference, as compared with vehicle, without affecting water intake. This effect was dose-dependent, developed gradually, and was sustained for up to 40 days, even after the introduction of an alcohol-deprivation period. The findings suggest that ORG 25935, and possibly other GlyT-1 inhibitors as well, could provide a new pharmacological treatment strategy for alcohol dependence or abuse [92].

Fig. (10).

Chemical structure of ORG 25935.


The distribution, density, and activity of GlyT-1 in the living human brain can be visualized noninvasively by the specific radioligands and positron emission tomography (PET), and single photon computed tomography (SPECT), and the receptor binding can be quantified by appropriate tracer kinetic models, which can be modified and simplified for particular applications. Therefore, in vivo PET/SPECT imaging of GlyT-1 in the human brain provides a method for quantitative study of the GlyT-1-related pathophysiology in schizophrenia. Researchers at Merck developed the novel radioligand [35S](S)-2-amino-4-chloro-N-(1-(4-phenyl-1-(propylsulfonyl)piperidin-4-yl]ethyl)benzamide ([35S]AC-PPB: Kd=1.9 nM) (Fig. 11) for GlyT-1 in the brain. Autoradiographic studies of rat and rhesus brain slices with [35S]ACPPB showed that specific binding sites were plentiful and nonhomogeneously distributed, with high levels of binding in the brainstem, cerebellar white matter, thalamus, cortical white matter and spinal cord gray matter. In vivo studies demonstrated displaceable binding of [35S]ACPPB in rat brain tissues following intravenous administration of this radioligand [93]. Investigators at Merck also developed the novel PET ligand [18F] 2,4-dichloro-N- ((1-(propylsulfonyl)-4-(6-fluoropyridin-2-yl) piperidin-4-yl)methyl)benzamide (CFPyPB) (Fig. 11) for GlyT-1 in the human brain [94].

Fig. (11).

Chemical structures of [35S](S)-2-amino-4-chloro-N-(1- (4-phenyl-1-(propylsulfonyl)piperidin-4-yl)ethyl)benzamide ([35S] ACPPB), and [18F] 2,4-dichloro-N- ((1-(propylsulfonyl)-4-(6- fluoropyridin-2-yl) piperidin-4-yl)methyl)benzamide ([18F]CFPy PB).

In addition, researchers at Glaxo developed the PET ligand [11C]GSK 931145 (Fig. 12) for GlyT-1 in the human brain [95,96]. [18F]CFPyPB and [11C]GSK 931145 would be potential PET ligands for in vivo visualization of GlyT-1 in the living human brain with PET. These PET ligands represent a new tool for the evaluation of glutamatergic neurotransmission in the pathophysiology of neuropsychiatric diseases, including schizophrenia.

Fig. (12).

Chemical structure of [11C]GSK 931145.


Sarcosine is generated by the enzymatic transfer of a methyl group from S-adenosylmethionine to glycine, and this reaction is catalyzed by the enzyme glycine N-methyltransferase [97,98]. Recently, sarcosine was identified as a biomarker that is highly increased during prostate cancer progression to metastasis and can be detected non-invasively in urine [99]. Interestingly, a recent population-based, nested, case-controlled study demonstrated a 40.7% lower risk of prostate cancer in male patients with schizophrenia [100]. It is thus likely that the sarcosine pathway plays a role in the lower risk for prostate cancer in male subjects with schizophrenia, although further detailed studies will be necessary to confirm this hypothesis [98].

Sarcosine is a safe drug, since it is synthesized in the human body. In fact, treatment with sarcosine (2 g/day) can benefit schizophrenic patients also being treated with antipsychotics, including risperidone [101], but not clozapine [102]. A randomized, double-blind, placebo-controlled study demonstrated that members of a sarcosine (2 g/day) group showed greater reductions in their Positive and Negative Syndrome Scale (PANSS) total scores than members of a placebo group or D-serine (2 g/day) group, suggesting that sarcosine is superior to D-serine in that benefits both patients with long-term stable disease and also acutely ill persons with schizophrenia [103]. Furthermore, a randomized, double-blind study reported that sarcosine (2 g/day) alone was effective in the treatment of acutely symptomatic drug-free patients with schizophrenia [104]. Further large-sized, placebo-controlled, dose-finding studies are needed to fully assess the effects of sarcosine, since these reports regarding the beneficial effects of sarcosine were based on small studies from the same group in Taiwan. In contrast, Zhang et al. [105] reported that sarcosine is an NMDA receptor co-agonist that differs from glycine, suggesting that co-agonistic activity at the NMDA receptors of sarcosine may, in part, be involved in the clinical benefits of this drug in schizophrenia. Nonetheless, all these findings suggest that GlyT-1 inhibition could be a novel pharmacotherapeutic target for enhancing NMDA receptor function.

Very recently, Liem-Moolenaar et al. [106] reported the effects of the GlyT-1 inhibitor R 231857 (Fig. 13) on the CNS and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. R231857 had some small effects on scopolamine-induced CNS-impairment, which were also not clearly dependent on dose. Scopolamine proved to be an accurate, reproducible and safe model for the induction of CNS impairment by an anticholinergic mechanism. R231857 lacked consistent dose-related effects in this study, probably because the CNS concentrations were too low to produce significant/reproducible CNS effects or to affect the scopolamine challenge in healthy volunteers. The effects of higher doses in healthy volunteers and the clinical efficacy in patients remain to be established. To date, clinical findings with GlyT-1 inhibitors are limited because of the early stage of development of the most high-affinity compounds.

Fig. (13).

Chemical structure of R231857.


As described above, the glycine modulatory sites on NMDA receptors are among the most attractive targets for developing potential therapeutic drugs for the treatment of schizophrenia. One means of enhancing NMDA receptor function would be to pharmacologically increase synaptic glycine levels by GlyT-1 inhibitors. At present, a number of pharmaceutical companies are developing novel and selective GlyT-1 inhibitors for the treatment of schizophrenia [43-55]. Gaining a better understanding of the role of GlyT-1 in the treatment of schizophrenia is expected to provide new perspectives for treating this disorder. Finally, the pharmacological modulation of glycine modulatory sites on NMDA receptors by non-sarcosine-derived GlyT-1 inhibitors could be beneficial in the treatment of the cognitive deficits and psychosis associated with several psychiatric diseases, including schizophrenia.


This study was supported in part by a grant from the Minister of Education, Culture, Sports, Science, and Technology of Japan (to K.H.), and by a grant from the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation of Japan (to K.H.).


[1] Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia Am J Psychiatry 1991; 148: 1301-8.
[2] Olney J W, Farber N B. Glutamate receptor dysfunction and schizophrenia Arch Gen Psychiatry 1995; 52: 998-1007.
[3] Coyle JT. The glutamatergic dysfunction hypothesis for schizophrenia Harv Rev Psychiatry 1996; 3: 241-53.
[4] Krystal J H, D'Souza D C, Petrakis I L, et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders Harv Rev Psychiatry 1999; 7: 125-43.
[5] Goff D C, Coyle J T. The emerging role of glutamate in the pathophysiology and treatment of schizophrenia Am J Psychiatry 2001; 158: 1367-77.
[6] Tsai G, Coyle J T. Glutamatergic mechanisms in schizophrenia Annu Rev Pharmacol Toxicol 2002; 42: 165-79.
[7] Coyle J T, Tsai G. The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia Psychopharmacology 2004; 174: 32-8.
[8] Hashimoto K, Fukushima T, Shimizu E, et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the NMDA receptor hypofunction hypothesis of schizophrenia Arch Gen Psychiatry 2003; 60: 572-6.
[9] Hashimoto K, Okamura N, Shimizu E, Iyo M. Glutamate hypothesis of schizophrenia and approach for possible therapeutic drugs Curr Med Chem - CNS Agents 2004; 4: 147-54.
[10] Hashimoto K, Shimizu E, Iyo M. Dysfunction of glia-neuron communication in pathophysiology of schizophrenia Curr Psychiatry Rev 2005; 1: 151-63.
[11] Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs Clin Psychopharmacol Neurosci 2006; 4: 3-10.
[12] Hashimoto K, Hattori E. Sawa A, McInnis M. Candidate genes and models. Neurotransmission In: Neurogenetics in Psychiatry: Scientific Understanding and Clinical Applications. New York: Taylor & Francis Group 2007; pp. 81-100.
[13] Luby E D, Cohen B D, Rosenbaum G, Gottlieb J S, Kelley R. Study of a new schizophrenomimetic drug; sernyl AMA Arch Neurol Psychiatry 1959; 81: 363-9.
[14] Allen R M, Young S J. Phencyclidine-induced psychosis Am J Psychiatry 1978; 135: 1081-4.
[15] Krystal J H, Karper L P, Seibyl J P, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses Arch Gen Psychiatry, 1994; 51: 199-214.
[16] Malhotra A K, Pinals D A, Weingartner H, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers Neuropsychopharmacology 1996; 14: 301-7.
[17] Hartvig P, Valtysson J, Lindner KJ, et al. Central nervous system effects of subdissociative doses of (S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers Clin Pharmacol Ther 1995; 58: 165-73.
[18] Lahti A C, Koffel B, LaPorte D, Tamminga C A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia Neuropsychopharmacology 1995; 13: 9-19.
[19] Zarate Jr C A, Singh J B, Carlson P J, et al. A randomized trial of an N- methyl-D-aspartate antagonist in treatment-resistant major depression Arch Gen Psychiatry 2006; 63: 856-64.
[20] Maeng S, Zarate C A. The role of glutamate in mood disorders: results from the ketamine in major depression study and the presumed cellular mechanism underlying its antidepressant effects Curr Psychiatry Rep 2007; 9: 467-74.
[21] Machado-Vieira R, Salvadore G, Diazgranados N, Zarate C A Jr. Ketamine and the next generation of antidepressants with a rapid onset of action Pharmacol Ther 2009; 123: 143-50.
[22] Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder Brain Res Rev 2009; 61: 105-23.
[23] Aprison MH, Werman R. The distribution of glycine in cat spinal cord and roots Life Sci 1965; 4: 2075-83.
[24] Curtis D R, Hosli L, Johnston G A. Inhibition of spinal neurons by glycine Nature 1967; 215: 1502-3.
[25] Semba T, Kano M. Glycine in the spinal cord of cats with local tetanus rigidity Science 1969; 164: 571-2.
[26] Aragon C, Lopez-Corcuera B. Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion Trends Pharmacol Sci 2005; 26: 283-6.
[27] Eulenburg V, Armsen W, Betz H, Gomeza J. Glycine transporters: essential regulators of neurotransmission Trends Biochem Sci 2005; 30: 325-33.
[28] Zafra F, Aragon C, Gimenez C. Molecular biology of glycinergic neurotransmission Mol Neurobiol 1997; 14: 117-42.
[29] Danysz W, Parsons A C. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications Pharmacol, Rev 1998; 50: 597-664.
[30] Waziri R, Baruah S, Hegwood T S, Sherman A D. Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics Neurosci Lett 1990; 120: 237-40.
[31] Waziri R, Baraiah S, Sherman A D. Abnormal serine-glycine metabolism in the brains of schizophrenics Schizophrenia Res 1992; 8: 233-43.
[32] Heresco-Levy U, Javitt D C. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis Schizoph Res 2004; 66: 89-96.
[33] Smith K E, Borden L A, Hartig P R, Branchek T, Weinshank R L. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors Neuron 1992; 8: 927-35.
[34] Borowsky B, Mezey E, Hoffman B J. Two glycine transporter variants with distinct localization in the CNS and peripheral tissues are encoded by a common gene Neuron 1993; 10: 851-63.
[35] Liu Q R, Lopez-Corcuera B, Mandiyan S, Nelson H, Nelson N. Molecular characterization of four pharmacologically distinct gamma-aminobutyric acid transporters in mouse brain J Biol Chem 1993; 268: 2106-12.
[36] Kim K M, Kingsmore S F, Han H, et al. Cloning of the human glycine transporter type 1: molecular and pharmacological characterization of novel isoform variants and chromosomal localization of the gene in the human and mouse genomes Mol Pharmacol 1994; 45: 608-17.
[37] Zafra F, Aragon C, Olivares L, Danbolt N C, Gimenez C, Storm-Mathisen J. Glycine transporters are differentially expressed among CNS cells J Neurosci 1995; 15(5 Pt 2): 3952-69.
[38] Zafra F, Gomeza J, Olivares L, Aragon C, Gimenez C. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS Eur J Neurosci 1995; 7: 1342-52.
[39] Cubelos B, Gimenez C, Zafra F. Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain Cereb Cortex 2005; 15: 448-59.
[40] Bergeron R, Meyer T M, Coyle J T, Greene R W. Modulation of N-methyl-D-aspartate receptor function by glycine transport Proc Natl Acad Sci USA 1998; 95: 15730-4.
[41] Gomeza J, Hulsmann S, Ohno K, et al. Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition Neuron 2003; 40: 785-96.
[42] Tsai G, Ralph-Williams R J, Martina M, et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype Proc Natl Acad Sci USA 2004; 101: 8485-90.
[43] Vandenberg R J, Aubrey K R. Glycine transport inhibitors as potential antipsychotic drugs Expert Opin Ther Targets 2001; 5: 507-18.
[44] Javitt D C. Glycine modulators in schizophrenia Curr Opin Investig Drugs 2002; 3: 1067-72.
[45] Millan M J. N-methyl-D-aspartate receptor-coupled glycineB receptors in the pathogenesis and treatment of schizophrenia: a critical review Curr Drug Targets CNS Neurol Disord 2002; 1: 191-213.
[46] Sur C, Kinney G G. The therapeutic potential of glycine transporter-1 inhibitors Expert Opin Investig Drugs 2004; 13: 515-21.
[47] Kinney G G, Sur C. Glycine site modulators and glycine transporter-1 inhibitors as novel therapeutic targets for the treatment of schizophrenia Curr Neuropsychopharmacol 2005; 3: 35-43.
[48] Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia Recent Pat CNS Drug Discov 2006; 1: 43-54.
[49] Lechner S M. Glutamate-based therapeutic approaches: inhibitors of glycine transport Curr Opin Pharmacol 2006; 6: 75-81.
[50] Lindsley C W, Wolkenberg S E, Kinney G G. Progress in the preparation and testing of glycine transporter type-1 (GlyT-1) inhibitors Curr Top Med Chem 2006; 6: 1883-96.
[51] Hashimoto K. Glycine transporter-1 inhibitors as novel therapeutic drugs for schizophrenia CNS Agents Med Chem 2007; 7: 177-82.
[52] Javitt D C. Glycine transport inhibitors and the treatment of schizophrenia Biol Psychiatry 2008; 63: 6-8.
[53] Yang C R, Svensson K A. Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia Pharmacol Ther 2008; 120: 317-32.
[54] Javitt D C. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification Curr Opin Drug Discov Dev 2009; 12: 468-78.
[55] Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia Front CNS Drug Discov 2009. in press
[56] Jentsch J D, Roth R H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia Neuropsychopharmacology 1999; 20: 201-25.
[57] Morris B J, Cochran S M, Pratt J A. PCP: from pharmacology to modelling schizophrenia Curr Opin Pharmacol 2005; 5: 101-6.
[58] Hashimoto K, Fujita Y, Shimizu E, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol Eur J Pharmacol 2005; 519: 114-7.
[59] Hashimoto K, Fujita Y, Ishima T, Hagiwara H, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of tropisetron: Role of α7 nicotinic receptors Eur J Pharmacol 2006; 553: 191-5.
[60] Hashimoto K, Fujita Y, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors Neuropsychopharmacology 2007; 32: 514-21.
[61] Hashimoto K, Ishima T, Fujita Y, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective α7 nicotinic receptor agonist SSR180711 Biol Psychiatry 2008; 63: 92-7.
[62] Fujita Y, Ishima T, Kunitachi S, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 336-9.
[63] Hagiwara H, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptor Eur Neuropsychopharmacol 2008; 18: 448-54.
[64] Hashimoto K, Fujita Y, Ishima T, Chaki S, Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of glycine transporter-1 inhibitor NFPS and D-serine Eur Neuropsychopharmacol 2008; 18: 414-21.
[65] Ishima T, Fujita Y, Kohno M, et al. Improvement of phencyclidine-induced cognitive deficits in mice by subsequent subchronic administration of fluvoxamine, but not sertraline Open Clin Chem J 2009; 2: 7-11.
[66] Kunitachi S, Fujita Y, Ishima T, et al. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of donepezil: role of sigma-1 receptors Brain Res 2009; 279: 189-93.
[67] Tanibuchi Y, Fujita Y, Kohno M, et al. Effects of quetiapine on phencyclidine-induced cognitive deficits in mice: a possible role of adrenergic α1 receptors Eur Neuropsychopharmacol 2009; 17: 861-7.
[68] Atkinson B N, Bell S C, De Vivo M, et al. ALX 5407: a potent, selective inhibitor of the hGlyT-1 glycine transporter Mol Pharmacol 2001; 60: 1414-20.
[69] Aubrey K R, Vandenberg R J. N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl] sarcosine (NFPS) is a selective persistent inhibitor of glycine transport Br J Pharmacol 2001; 134: 1429-36.
[70] Mallorga P J, Williams J B, Jacobson M, et al. Pharmacology and expression analysis of glycine transporter GlyT-1 with [3H]-(N-[3-(4'-fluorophenyl)-3-(4'phenylphenoxy)propyl])sarcosine Neuropharmacology 2003; 45: 585-93.
[71] Kinney G G, Sur C, Burno M, et al. The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior J Neurosci 2003; 23: 7586-91.
[72] Lipina T, Labrie V, Weiner I, Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia Psychopharmacology (Berl) 2005; 179: 54-67.
[73] Karasawa J, Hashimoto K, Chaki S. D-serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats Behav Brain Res 2008; 186: 78-83.
[74] Manahan-Vaughan D, Wildforster V, Thomson C. Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT-1) Eur J Neurosci 2008; 28: 1342-50.
[75] Depoortere R, Dargazanli G, Estenne-Bouhtou G, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic Neuropsychopharmacology 2005; 30: 1963-85.
[76] Leonetti M, Desvignes C, Bougault I, Souilhac J, Oury-Donat F, Steinberg R. 2-Chloro-N-[(S)-phenyl [(2S)-piperidin-2-yl] methyl]-3-trifluoromethyl benzamide, monohydrochloride, an inhibitor of the glycine transporter type 1, increases evoked-dopamine release in the rat nucleus accumbens in vivo via an enhanced glutamatergic neurotransmission Neuroscience 2006; 137: 555-64.
[77] Gozzi A, Herdon H, Schwarz A, et al. Pharmacological stimulation of NMDA receptors via co-agonist site suppresses fMRI response to phencyclidine in the rat Psychopharmacology (Berl) 2008; 201: 273-84.
[78] Black M D, Varty G B, Arad M, et al. Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat Psychopharmacology (Berl) 2009; 202: 385-96.
[79] Singer P, Feldon J, Yee B K. Interactions between the glycine transporter 1 (GlyT-1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour Eur Neuropsychopharmacol 2009; 19: 571-80.
[80] Boulay D, Pichat P, Dargazanli G, et al. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia Pharmacol Biochem Behav 2008; 91: 47-58.
[81] Lindsley C W, Zhao Z, Leister W H, et al. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT-1) inhibitors derived from a series of [4-phenyl-1-(propyl-sulfonyl)piperidin-4-yl]methyl benzamides ChemMedChem 2006; 1: 807-11.
[82] Zhao Z, O'Brien J A, Lemaire W, et al. Synthesis and SAR of GlyT-1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides Bioorg Med Chem Lett 2006; 16: 5968-72.
[83] Pinard E, Ceccarelli S M, Stalder H, Alberati D. Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT-1 inhibitors Bioorg Med Chem Lett 2006; 16: 349-53.
[84] Ceccarelli S M, Pinard E, Stalder H, Alberati D. Discovery of N-(2-hydroxy-2-aryl-cyclohexyl) substituted spiropiperidines as GlyT-1 antagonists with improved pharmacological profile Bioorg Med Chem Lett 2006; 16: 354-7.
[85] Alberati D, Hainzl D, Jolidon S, et al. Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro [4.5]decan-1-one as a novel class of highly selective GlyT-1 inhibitors with improved metabolic stability Bioorg Med Chem Lett 2006; 16: 4311-5.
[86] Alberati D, Ceccarelli S M, Jolidon S, et al. Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT-1 inhibitors: achieving selectivity against the mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors Bioorg Med Chem Lett 2006; 16: 4305-10.
[87] Alberati D, Hainzl D, Jolidon S, et al. 4-Substituted-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT-1 inhibitors with superior pharmacological and pharmacokinetic parameters Bioorg Med Chem Lett 2006; 16: 4321-5.
[88] Pinard E, Alberati D, Borroni E, et al. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors Bioorg Med Chem Lett 2008; 18: 5134-9.
[89] Smith G, Ruhland T, Mikkelsen G, et al. The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as GlyT-1 inhibitors Bioorg Med Chem Lett 2004; 14: 4027-30.
[90] Smith G, Mikkelsen G, Eskildsen J, Bundgaard C. The synthesis and SAR of 2-arylsulfanylphenyl-1-oxyalkylamino acids as GlyT-1 inhibitors Bioorg Med Chem Lett 2006; 16: 3981-4.
[91] Ge J, Hamilton W, Shahid M, Hill D R, Walker G. The effects of ORG 25935 on the extracellular levels of glycine in brain regions of freely moving rats Brit J Pharmacol 2001; 133: 135p.
[92] Molander A, Lido H H, Lof E, Ericson M, Soderpalm B. The glycine reuptake inhibitor ORG 25935 decreases ethanol intake and preference in male Wistar rats Alcohol Alcohol 2007; 42: 11-8.
[93] Zeng Z, O'Brien J A, Lemaire W, et al. A novel radioligand for glycine transporter 1: characterization and use in autoradiographic and in vivo brain occupancy studies Nucl Med Biol 2008; 35: 315-25.
[94] Williams D L, Jennings A, Lewis R, et al. A novel glycine transporter-1 PET tracer: from discovery to clinic Abstr Neurosci 2008; 885: 15.
[95] Murthy N V, Passchier J, Gunn R N, et al. [11C]GSK 931145: a new PET ligand for glycine transporter 1 Neuroimage 2008; 41: T21.
[96] Passchier J, Murthy V, Catafau A, et al. Development and evaluation of [11C]GSK 931145, a new PET ligand for imaging type 1 glycine transporters (GlyT1) in the living human brain J Nucl Med 2008; 49(Suppl. 1): 129P.
[97] Abate-Shen C, Shen MM. The Prostate-cancer metabolome Nature 2008; 457: 799-800.
[98] Hashimoto K. Sarcosine and decreased risk for prostate cancer in schizophrenia Open Clin Chem J 2009; 2: 22-3.
[99] Sreekumar A, Poisson L M, Rajendiran T M, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression Nature 2009; 457: 910-4.
[100] Hippisley-Cox J, Vinogradova Y, Coupland C, Parker C. Risk of malignancy in patients with schizophrenia or bipolar disorder. Nested case-control study Arch Gen Psychiatry 2007; 64: 1368-76.
[101] Tsai G, Lane H Y, Yang P, Chong M Y, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia Biol Psychiatry 2004; 55: 452-6.
[102] Lane H Y, Huang C L, Wu P L, et al. Glycine transporter 1 inhibitor, N-methylglycine (sarcosine), added to clozapine for the treatment of schizophrenia Biol Psychiatry 2006; 60: 645-9.
[103] Lane HY, Chang Y C, Liu Y C, Chiu C C, Tsai G E. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study Arch Gen Psychiatry 2005; 62: 1196-204.
[104] Lane HY, Liu Y C, Huang C L, et al. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study Biol Psychiatry 2008; 63: 9-12.
[105] Zhang H X, Hyrc K, Thio L L. The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine J Physiol 2009; 587: 3207-20.
[106] Liem-Moolenaar M, Zoethout R, de Boer P, et al. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects J Psychopharmacol 2009. Epub ahead of print